Ixazomib/Enleri vs. Bortezomib: Which proteasome inhibitor has the advantage?

Ixazomib (also known as Ixazomib) and bortezomib (bortezomib) both belong to the proteasome inhibitor category among targeted anti-cancer drugs. They have similar anti-cancer mechanisms and both work by interfering with the survival process of cancer cells. As a pioneer of this type of drug, bortezomib has accumulated rich experience in the treatment of multiple myeloma since its approval in 2003. Subsequently, ixazomib was launched in 2015 as a new generation of oral drugs, and its convenient administration provides patients with new treatment options.

When discussing the advantages of these two drugs, we can compare them in several ways.

1. Convenience of medication

Ixazomib is available as an oral capsule and only needs to be taken once a week, which brings great convenience to patients. In contrast, bortezomib is administered intravenously or subcutaneously, usually twice or once a week. Therefore, ixazomib undoubtedly has significant advantages in terms of medication convenience.

2. Side effects and tolerance

Clinical trial results show that ixazomib performs well in reducing side effects compared with bortezomib. In particular, peripheral neuropathy (PN), a common side effect, was less frequent and less severe in the ixazomib trials. In addition, ixazomib reduced the incidence of side effects such as neutropenia, anemia, and herpes zoster. These advantages make ixazomib superior in terms of tolerability, and patients are more likely to continue taking the drug without interrupting treatment or adjusting dosage.

3. Efficacy and indications

Although ixazomib and bortezomib are similar in overall response rates, their indications are slightly different. Ixazomib is primarily used to treat multiple myeloma, while bortezomib is also used to treat mantle cell lymphoma. When choosing a drug, doctors make decisions based on a patient's specific condition and treatment history.

In summary, ixazomib and bortezomib each have their own advantages. For patients seeking medication convenience and better tolerability, ixazomib may be a better choice. However, bortezomib remains an effective treatment option for patients who are accustomed to and receive injectable therapy. The final choice should be based on the patient's individual situation and the professional advice of the doctor.